Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (SE:IMMU)
:IMMU
IMMU Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr4.46 - kr11.00
Previous CloseN/A
Volume3.78K
Average Volume (3M)37.81K
Market Cap
kr379.70M
Enterprise ValueN/A
Total Cash (Recent Filing)kr101.91M
Total Debt (Recent Filing)kr21.86M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding52,084,580
10 Day Avg. Volume70,085
30 Day Avg. Volume37,809
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)0.58
Price to Sales (P/S)0.00
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IMMU FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was kr4.46 and its highest was kr11.00 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is kr379.70M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is Aug 21, 2025 which is in 61 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on May 06, 2025. The company reported -kr0.605 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.605.
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 52,084,580 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -kr0.605 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.688%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in SE:IMMU
Company Description
Immunicum AB
Immunicum AB is a biotechnology company focused on developing novel immune therapies for the treatment of various cancer types. The company operates within the life sciences sector and is dedicated to leveraging its proprietary technology platforms to create innovative solutions that enhance the body's ability to recognize and combat cancer. Its core product offerings are centered around allogeneic dendritic cell-based therapies aimed at improving patient outcomes in oncology.
Technical Analysis
Guard Therapeutics International AB
―
Isofol Medical AB
―
Intervacc AB
―
Xbrane Biopharma AB
―
Xintela AB
―